Repligen beefs up cell therapy business with $1.5 billion deal for BioLife
Repligen beefs up cell therapy business with $1.5 billion deal for BioLife Reuters
Repligen beefs up cell therapy business with $1.5 billion deal for BioLife Reuters
Summary aggregated from Reuters's public RSS feed. The full reporting belongs to Reuters — please read it on their site.